Provided by Tiger Trade Technology Pte. Ltd.

IDEAYA Biosciences

37.59
+0.14000.37%
Post-market: 37.590.00000.00%19:30 EDT
Volume:429.25K
Turnover:16.16M
Market Cap:3.62B
PE:-19.22
High:38.27
Open:37.74
Low:37.24
Close:37.45
52wk High:42.68
52wk Low:24.24
Shares:96.27M
Float Shares:94.37M
Volume Ratio:0.75
T/O Rate:0.45%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.9561
EPS(LYR):-1.2849
ROE:-16.22%
ROA:-11.54%
PB:3.02
PE(LYR):-29.25

Loading ...

BUZZ-U.S. STOCKS ON THE MOVE-Energy shares, miners, Sysco

Reuters
·
Mar 30

BUZZ-Ideaya rises as it starts early-stage trial of combination of cancer drugs

Reuters
·
Mar 30

IDEAYA starts Phase 1 trial of IDE849-IDE161 combo in DLL3 solid tumors

Reuters
·
Mar 30

IDEAYA Biosciences Announces First-Patient-in for Phase 1 Combination Study of Ide849, Dll3 Top1 ADC, and Ide161, Parg Inhibitor, in Dll3 Upregulated Solid Tumor Indications, Including Sclc, Nets, Necs, and Melanoma

THOMSON REUTERS
·
Mar 30

IDEAYA Biosciences Inc - Targets Clinical Data Update for Ide849 and Ide161 in H2 2026

THOMSON REUTERS
·
Mar 30

Analysts’ Top Healthcare Picks: Tarsus Pharmaceuticals (TARS), IDEAYA Biosciences (IDYA)

TIPRANKS
·
Mar 28

IDEAYA Biosciences grants 49,000 inducement stock options; exercise price set at $32.09

Reuters
·
Mar 27

IDEAYA Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Mar 27

Assessing IDEAYA Biosciences (IDYA) Valuation After Recent Share Price Weakness

Simply Wall St.
·
Mar 24

Ideaya Biosciences updates guidance related to timing of Phase 2/3 data release

TIPRANKS
·
Mar 23

Ideaya Biosciences falls -6.0%

TIPRANKS
·
Mar 23

Analysts’ Top Healthcare Picks: Madrigal Pharmaceuticals (MDGL), IDEAYA Biosciences (IDYA)

TIPRANKS
·
Mar 23

J.P. Morgan Sticks to Its Buy Rating for IDEAYA Biosciences (IDYA)

TIPRANKS
·
Mar 23

IDEAYA Biosciences: Operational Trial Delay but High Conviction Buy Ahead of Key Darovasertib Readout

TIPRANKS
·
Mar 23

IDEAYA forecasts OptimUM-02 trial database lock in April 2026

Reuters
·
Mar 22

IDEAYA Biosciences to host darovasertib OptimUM-02 topline results webcast and attend Bank of America health care conference

Reuters
·
Mar 22

IDEAYA Biosciences Upcoming Investor Relations Events and Updated Darovasertib Topline Results Guidance From Phase 2/3 Optimum-02 Trial

THOMSON REUTERS
·
Mar 22

IDEAYA Biosciences to present three posters at AACR Annual Meeting

Reuters
·
Mar 18

IDEAYA Biosciences (IDYA) Gets a Buy from Mizuho Securities

TIPRANKS
·
Mar 17